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N6-methyl-adenosine (m6A) modification is the most abundant internal modification in mammalian RNA and 
plays an important role in gene expression mechanisms such as mRNA splicing, nuclear export, transcript 
stability and translational efficiency. The extent and the significance of m6A modifications in pathological 
conditions, especially hematological malignancies such as lymphomas are not known. In this study, the global 
m6A methylation by an immunocapture method in normal B cells (GMO 6990), and in the B cell neoplastic cells 
such as diffuse large B cell lymphoma (DB), Burkitt’s lymphoma (Raji) and a relapsed pre-B cell acute 
lymphoblastic leukemia (ALL) (NALM6) cells are discussed. Variable mRNA expression of RNA methylases 
such as methyltransferase like 3 (METTL3) and Wilms tumor 1 associated protein (WTAP) that methylates 
internal adenosine residues in mRNA was observed in normal and lymphoma cells as quantified by qRT-PCR. 
Further, an mRNA demethylase, Fat mass and obesity associated enzyme (FTO) mRNA expression was found to 
be high in lymphoma cells compared to normal B cells. A similar trend was also observed between normal and 
ALL patients at diagnosis. Overall, our studies suggest that altered RNA methylation and enzymes controlling 
this process may be of significance in the pathology of lymphoid malignancies. 
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Introduction 
Lymphoid neoplasms are the fourth most common cancer 
and sixth leading cause of cancer death in the United States 
[1]. Non-Hodgkin lymphoma (NHL) is a subtype of lymphoid 
neoplasm that includes B cell acute lymphoblastic leukemia 
(pre B ALL), diffuse large B cell lymphoma (DLBCL) and 
Burkitt’s lymphoma (BL). The incidence of pre-B ALL has 
increased since 2003 and primarily affects the pediatric 
population [1]. DLBCL is much more common in adults and 
the incidence increases with age. BL is relatively rare, but it 
is one of the most common types of childhood lymphoma [1] 
and can also occur in older adults. At the molecular level, 
Non-Hodgkin lymphoma presents with heterogeneous 
features including chromatin modifications and epigenetic 
alterations such as methylation of DNA that contribute to 
lymphomagenesis [2]. Akin to DNA modification, RNA 
methylation (e.g. N6-methyl adenosine, m6A) is also present 
in various RNA including mRNA and long non-coding RNA 
(lncRNA) [3], and may constitute another layer of epigenetic 
regulation of gene expression in lymphoma.  
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Table 1. Different primers used in this study 
Genes Primers 
METTL3 F: 5’-CTACAGGATGATGGCTTTCTC- 3’ 
R: 5’-ATTTCATCTACCCGTTCATACC-3’ 




ALKBH5 F: 5’-TGGTCCTGACCTCTCTTATC-3’ 
R: 5’- CTACCACACACCACAACAA-3’ 
The most abundant internal mRNA modification in 
eukaryotes is N6-methyl adenosine (m6A). An estimated 
three to five m6A sites were reported to be present in one 
single mRNA [4]. RNA methylation is non-randomly 
distributed and enriched around transcription start sites, long 
internal exons and stop codons [5]. Also, m6A methylation is 
highly enriched in the last coding sequences of the majority 
of genes and this modification leads to widespread effects on 
gene expression, development and protein termination [6]. 
Although certain mRNA regions are enriched with m6A 
modification the function of such enrichment in RNA is 
currently unknown. The biological functions attributed to 
m6A modification on mRNA include modification of mRNA 
splicing, nuclear export, stability and translational efficiency 
[5], indicating that methylation is correlated with unique 
regulatory functions. Exactly, how the m6A distribution 
varies in mRNA of normal vs diseased cells needs to be 
determined.   
The m6A modification of mRNA functions as a dynamic 
mark that is post-transcriptionally installed and erased by 
m6A methylases and demethylases. Also, more than one 
methylase or demethylase has been reported to be involved 
in m6A modification [7]. Methyl transferase like-3 
(METTL3/MT-A70), is an RNA methylase that installs m6A 
modification in mammalian mRNA as a part of 
methyltransferase complex [8]. METTL3 is observed both in 
the nucleus and cytoplasm, suggesting that RNA methylation 
could occur in both cell compartments [9, 10]. As mentioned 
above, m6A modification is important for several cellular 
functions, stem cell differentiation, and RNA editing [11, 12]. 
On the other hand, m6A demethylases are also important for 
the dynamic regulation of RNA m6A modification. Fat mass 
and obesity associated (FTO) enzyme was reported to 
possess RNA demethylase function [13] and is one of the 
enzymes largely explored with respect to m6A modification. 
FTO preferentially removes methyl groups from single 
stranded RNA (ssRNA) by means of oxidation, but it can 
also target double stranded RNA, albeit with low affinity [13,
14]. Thus, both METTL3 and FTO play an important role in 
RNA regulation and processing. Alteration in the quantity or 
efficiency of these molecules will affect RNA processing and 
could help drive cancer phenotypes.  
It is hypothesized that the m6A content in mRNA from 
lymphoma cells will be lower compared to normal cells and 
the enzyme(s) involved in m6A demethylation may be higher 
in lymphoid malignancies. To test our hypothesis, we 
explored the total m6A methylation profiles in various 
lymphoid malignant cells and normal B cells by direct 
extraction of mRNA and utilizing an immunocapture method 
with antibodies specific for N6-methyladenosine (m6A). We 
also investigated the mRNA expression of factors controlling 
m6A modifications in these cells. Our preliminary results 
indicate a lower mRNA methylation trend in different 
lymphoma cells as well as an increased expression of m6A 
demethylase suggesting that alteration in m6A modification 
may play an important role in lymphoid malignancies. 
Materials and methods 
Cell lines. Diffuse large B-cell lymphoma (DB), Burkitt’s 
lymphoma (Raji), relapsed Pre-B acute lymphoblastic cells 
(NALM6) were maintained in complete RPMI media with 
10% FBS. Normal B cells (GM06990) were maintained in 
complete RPMI media containing 15% FBS. Only cells in 
the early passages (<5) were used in our experiments.  All 
lymphoma cells were tested for authenticity using STR 
(IDEXX BioResearch, West Sacramento, CA), interspecies 
contamination, and mycoplasma contamination. 
mRNA isolation. The cellular mRNA was prepared using 
the GeneElute direct mRNA miniprep kit (Sigma, St Louis, 
MO) as described in the kit protocol. In brief, the cells (106 
cells each) were lysed and homogenized on ice followed by 
digestion with proteinase K to eliminate RNase. 
Subsequently, after addition of sodium chloride the 
polyadenylated RNA was captured on oligo (dt) polystyrene 
beads and eluted using 10 mM Tris-HCl (pH 7.4). To avoid 
any trace contamination of DNA, the samples were treated 
with RNase-free DNAse1 (Qiagen, Germantown, MD). 
Further, in order to inhibit residual RNase in the sample, 
RNasin ribonuclease inhibitor (50-100 U) (Promega, 
Madison, WI) was added to the sample preparations 
according to the manufacturer’s protocol. 
Enzyme-Linked Immunosorbent Assay (ELISA). The 
m6A methylation in mRNA was quantified using a specific 
RNA & DISEASE 2019; 6: e1563. doi: 10.14800/rd.1563; © 2019 by Senthil R. Kumar, et al. 
http://www.smartscitech.com/index.php/rd 
Page 3 of 6 
N6-methyladenosine capture antibody according to the 
manufacturer’s protocol (Abcam, Cambridge, MA). Briefly, 
from the mRNA isolated from the above step 150-200 ng 
was added to the wells in a 96 well plate containing the 
binding solution (80 µl). Positive and negative controls 
(supplied by the manufacturer) were also processed in 
parallel. Subsequently, the capture antibody was added to the 
wells and incubated for 90 min. After washing the wells 
using the wash buffer the detection antibody was added to 
the wells and incubated for 30 min. After further washing, 
the enhancer solution was added to the wells and incubated 
for additional 30 min. For signal detection, the developer 
solution was added and incubated for 10 min. After addition 
of a stop solution the absorbance (450 nm) was measured in 
a microplate reader. The results are depicted as m6A content 
in sample cellular mRNA’s. Two technical replicates were 
performed for each sample.  
Real-time quantitative PCR (qRT-PCR) analysis. Total 
RNA from different lymphoma and normal cells were 
extracted using RNeasy mini kit (Qiagen, Valencia, CA). 
cDNA was generated from total RNA using cDNA synthesis 
kit (Bio-rad, Hercules, CA). Quantitative real-time PCR 
(qRT-PCR), was performed with CFX Connect and a Sybr 
Green reaction (Biorad). The data was analyzed using 2-ΔΔCT 
method to assess fold change in mRNA expression. Gene 
expression levels were normalized against 18sRNA for 
individual samples. The primer sequences for the genes used 
in this study are depicted in Table 1.  
Collection of patient samples. Bone marrow samples from 
normal healthy donors and pre-B lymphoblastic leukemia 
patients (pre-B ALL) (de-identified) were obtained upon 
ethical approval by the Institutional Review Board, 
University of Missouri. ALL patient samples contained at 
least 88% blasts. The mononuclear cells from the bone 
marrow samples were isolated as described previously [15].  
RNA-seq analysis. Total RNA was isolated from the 
normal and ALL patient samples. RNA-seq libraries were 
constructed using NEBNext® UltraTM Directional RNA 
Library Prep Kit for Illumina® (New England Biolabs). The 
sequencing was done using Illumina HiSeq 2000 (1x100 bp 
reads). 
Processing and RNA-seq read mapping. 100 bp single-end 
RNA-seq reads were obtained from Illumina HiSeq 2000. 
Sequence files were generated in FASTQ format. RNA-seq 
data were analyzed using  Perl programming on Unix/Linux 
based system (64-bit computer running Linux; 4 GB of 
RAM). The quality score of RNA-seq reads was obtained by 
using the FastX-Toolkit v. 0.0.13. Reads were 
Figure 1. RNA m6A methylation. a) m6A methylation in RNA facilitated by methylase enzymes such as METTL3 and WTAP. Demethylases 
such as FTO and ALKBH5 removes the methyl groups from the adenosine base. b) m6A sites in mRNA can influence the interaction of the RNA 
binding proteins. RRACU, methylation consensus region (vertical lines); m6A, grey pins; exons, thick colored bars; introns, thin lines. 
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then processed and aligned to the UCSC H. sapiens reference 
genome (build hg19) using TopHat v1.3.3 [16]. 
Statistical analysis. All the experiments were performed in 
triplicates (unless mentioned otherwise) and the data are 
expressed as mean ±SD. Statistical significance was 
evaluated using Student’s t test. P value <0.05 was 
considered significant. 
Results and discussion 
The m6A modification in mRNA is particularly intriguing 
(Figure 1), and on average three to five m6A modifications 
occur in each mRNA [5]. While the m6A modification has 
been shown to be associated with different diseases [4, 17, 18], 
the m6A methylation status in lymphoid malignancies is 
unknown. To determine whether mRNA from normal human 
B cells and from malignant B cells have variable total m6A 
content, mRNA was directly isolated from GM06990 
(normal B cells) and B cell lymphoma subtypes (DLBCL 
(DL), Raji (BL) and NALM6 (pre-B ALL cells from a 
relapsed patient). Isolated mRNA was processed further to 
detect total m6A content by an immunocapture method using 
an antibody specific for m6A. The results indicated that m6A 
methylation, though variable, is low in all the lymphoma 
cells tested compared to normal B-cells (Figure 2A), 
suggesting that alteration in mRNA specific methylation 
modifications occur in lymphoid malignant cells. Even 
within the lymphoma cell subtypes, DB cells had the lowest 
detectable m6A content compared to other malignant cells 
Figure 2. A. m6A content in normal B cells and different lymphoid malignant cells. Immunocapture assay depicting the 
amount of m6A content in mRNA of the cells analyzed. Pos con – positive control; Neg con-negative control (n=3 for each 
cells). B. qRT-PCR for mRNA expression of m6A modifiers. mRNA expression of a) METTL3 and WTAP. Results are from 
three experimental replicates. C. qRT-PCR for mRNA expression of FTO and ALKBH5. Results are from three experimental 
replicates. D. METTL3 and FTO expression in patient samples. Whole transcriptomic and subsequent bioinformatic 
analysis (see methods) for RNA expression of normal and ALL patient bone marrow samples (n=8 each) indicated METTL3 
is lower (P=0.02) and FTO is higher (P < 0.01) compared to normal. 
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further suggesting a cellular context dependent mode of m6A 
modification. This is in keeping with the reports that m6A 
modifications have distinct distributions among different 
tissues indicating each cell type and cell state may have 
unique m6A modification patterns [19]. The m6A modification 
in mRNA is a dynamic process and may involve in important 
functions such as cellular homeostasis [17]. Further, in 
embryonic stem cells (ESC), depletion of m6A modifications 
blocked differentiation and led to hyper-naive pluripotent 
state [7]. Our observations that a decreased m6A trend in 
lymphoma cells may be suggestive of continuous cell 
proliferation and reduced differentiation resulting in more 
immature lymphocytes, although further studies are needed 
to confirm this possibility.  
The decreased m6A in lymphoma raised the question 
whether the factors, specifically the enzymes, involved in the 
m6A modifications may be differentially expressed in normal 
vs lymphoid malignant cells? To explore this, we 
investigated the gene expression of two mRNA methylases, 
METTL3 and WTAP as well as two different mRNA 
demethylases, FTO and ALKBH5 in normal and malignant 
lymphoid cells. The mRNA expression of methylase enzyme, 
METTL3, was relatively higher in all the lymphoma cells 
compared to normal B cells, whereas, WTAP mRNA 
expression was observed to be high only in NALM6 cells 
(Figure 2B). While METTL3 and WTAP are required for 
m6A modifications, a previous report using siRNA depletion 
experiments suggested that another enzyme, KIAA1429, 
associated with methyltransferase complex was required for 
the full methylation program in mammals [20]. Overall, it 
appears that mRNA methylation in general requires multiple 
components as a part of the methyltransferase complex for 
efficient RNA methylation which again could vary 
depending on the cellular phenotypes and the disease 
process.  
Gene expression analysis of mRNA demethylases 
indicated that FTO mRNA expression was higher in all the 
lymphoma cells tested with increased cellular expression in 
the following order (DB>Raji>NALM6) (Figure 2C). 
However, gene expression of ALKBH5, also a demethylase 
was less compared to FTO in all the lymphoma cells. The 
mechanisms of demethylation between FTO and ALKBH5 
are different. While FTO functions via oxidative 
demethylation [21], ALKBH5 catalyzes the direct removal of 
methyl group from m6A-methylated adenosine. Further, apart 
from m6A, other nuclear RNAs were also found to be 
substrates for ALKBH5 [22]. As per our observations, despite 
the expression of METTL3 in lymphoma cells the total m6A 
content as measured by immunocapture method was found to 
be low (Figure 2A). We speculate that the decreasing trend of 
m6A methylation in lymphoma cells could be in part due to 
increased expression of FTO in these cells. 
To determine if the trends observed in cell lines are 
consistent in primary cells, data generated from pre-B ALL 
patients and normal precursor B-cells was analyzed [23]. In 
these samples the gene expression of METTL3 was lower 
while FTO was higher in patients diagnosed with ALL 
compared to healthy donors (Figure 2D), although the m6A 
status in these samples needs to be determined. Interestingly, 
in our studies with relapsed ALL cells (NALM6) we found 
an increased METTL3 and moderate expression of FTO 
(Figure 2B &C). While our initial studies shed some light on 
the m6A modification in lymphoma cells and status of the 
enzymes involved in this process, our ongoing and future 
studies will be focused on the comprehensive roles of m6A 
methylation and the factors controlling such modifications in 
patients with lymphoid malignancies. 
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